Danaher Corporation $DHR Position Lifted by Krilogy Financial LLC

Krilogy Financial LLC raised its position in Danaher Corporation (NYSE:DHR) by 104.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 23,336 shares of the conglomerate’s stock after purchasing an additional 11,906 shares during the quarter. Krilogy Financial LLC’s holdings in Danaher were worth $5,170,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. EP Wealth Advisors LLC purchased a new position in Danaher during the 2nd quarter worth approximately $3,807,000. Puzo Michael J acquired a new position in shares of Danaher during the second quarter worth about $8,624,000. Madison Asset Management LLC acquired a new stake in Danaher in the second quarter valued at about $85,451,000. First Nebraska Trust Co acquired a new position in Danaher during the 2nd quarter worth approximately $14,106,000. Finally, Colton Groome Financial Advisors LLC purchased a new position in shares of Danaher during the 3rd quarter worth approximately $592,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Barclays boosted their price objective on shares of Danaher from $230.00 to $255.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. The Goldman Sachs Group boosted their price objective on shares of Danaher from $210.00 to $250.00 and gave the stock a “buy” rating in a research report on Monday, September 21st. Morgan Stanley lifted their price objective on Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a research report on Monday. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $240.00 price objective on shares of Danaher in a research report on Wednesday, July 22nd. Finally, UBS Group initiated coverage on shares of Danaher in a research report on Wednesday, September 9th. They issued a “buy” rating and a $250.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $235.41.

Danaher Price Performance

DHR opened at $223.30 on Wednesday. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The company has a fifty day simple moving average of $212.41 and a 200 day simple moving average of $195.13. The firm has a market cap of $156.98 billion, a price-to-earnings ratio of 39.66, a PEG ratio of 2.78 and a beta of 0.76. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. The firm had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. Danaher’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.77 earnings per share. Equities research analysts expect that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s payout ratio is 28.42%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.